Author

P. Phojanakong

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 4 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

V. Steri· 3 shared A. P. Wiita· 2 shared C. C. Smith· 2 shared C. Kasap· 2 shared E. Stieglitz· 2 shared P. Choudhry· 2 shared Y.-H. T. Lin· 2 shared A. D. Leavitt· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

V. Steri

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 1, 2022

Allosteric SHP2 Inhibition Increases Apoptotic Dependency on BCL2 and Synergizes with Venetoclax in FLT3- and KIT- Mutant AML

B. Popescu, C. Stahlhut, T. C. Tarver…·C. C. Smith

This study shows that combining SHP2 and BCL2 inhibition synergistically kills FLT3- and KIT-mutant AML cells and xenografts.

DOI 10.1101/2022.12.01.518665

humanproteomics

Cancer BiologybioRxivPreprintOct 10, 2022

Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target

K. Mandal, G. Wicaksono, C. Yu…·A. P. Wiita

The paper identifies an AML-specific conformation of Integrin-β2 using structural surfaceomics and demonstrates its targeting by CAR-T cells.

DOI 10.1101/2022.10.10.511511

humanproteomics

Cancer BiologybioRxivPreprintAug 4, 2021

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

P. Choudhry, C. Kasap, B. Patino Escobar…·A. Wiita

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

DOI 10.1101/2021.08.04.455165

Cancer BiologybioRxivFeb 3, 2019

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton…·A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

DOI 10.1038/s41467-020-15521-4

humanproteomics